Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $2.97B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.93M
Average 1.71M
DYN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Dyne Therapeutics, Inc.NASDAQ: DYN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $152.17M rose 53.3% year over year, ahead of the +17.2% change in trailing-twelve-month research & development. Sequentially, it rose 50.8% from the prior quarter. Over 3 fiscal years it compounded at +40.8% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +53.3% holds above the trailing-twelve-month pace of +17.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 398.33M USD
- Year-over-year change
- +41.6%
- 4-year CAGR
- +34.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 398.33M | +41.6% |
| FY2024 | 2024-12-31 | 281.41M | +33.5% |
| FY2023 | 2023-12-31 | 210.76M | +47.6% |
| FY2022 | 2022-12-31 | 142.76M | +17.7% |
| FY2021 | 2021-12-31 | 121.31M | — |
Research & Development vs competitors
How DYN compares with its peers on the latest reported figures
- DYN's LTM Jun 2026 research & development of $445.71M is the 3rd highest of the 11 companies compared; the peer median is $154.13M.
- Its year-over-year change of +17.2% is the 5th highest of 11, against a peer median of +12.4%.
- Over three fiscal years its annual growth of +40.8% compares with a peer median of +20.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $902.58M | -34.5% | +20.2% | 41.3% | |
| LTM Jun 2026 | $445.71M | +17.2% | +40.8% | — | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Mar 2026 | $189.6M | +13.6% | +16.4% | 264.1% | |
| LTM Mar 2026 | $155.55M | +43.4% | +21.4% | — | |
| LTM Mar 2026 | $152.7M | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $144.07M | +45.7% | +21.0% | 449.1% | |
| LTM Mar 2026 | $143.25M | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $92.92M | +60.8% | +57.0% | — | |
| LTM Mar 2026 | $58.35M | -32.7% | +9.5% | — | |
| Peer median (excluding DYN) | $154.13M | +12.4% | +20.6% | 180.1% | |
Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.46M | 2.24M | 2.05M |
| Gross Profit | 0 | 0 | (2.46M) | (2.24M) | (2.05M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
| Selling, General & Admin | 28.72M | 28.2M | 31.4M | 62.48M | 69.85M |
| Operating Expenses | 150.03M | 170.96M | 239.7M | 341.64M | 466.14M |
| Depreciation & Amortization | 1.09M | 1.68M | 1.67M | 1.67M | 2.05M |
| EBITDA | (148.2M) | (163.5M) | (234.26M) | (315.75M) | (437.97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (150.03M) | (170.96M) | (242.16M) | (343.89M) | (468.18M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 742K | 2.92M | 7.64M | 26.92M | 29.86M |
| Interest Expense | 0 | 2.92M | 0 | 0 | 6.19M |
| Other Income / Expenses | 734K | 2.86M | 6.23M | 26.47M | 21.97M |
| Income Before Tax | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| EPS (Diluted) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| Weighted Avg Shares | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M |
| Weighted Avg Shares (Diluted) | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M |
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$15.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.